The two stocks have been trending in different directions for months. Here's what that says about the broader market.
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
1d
Com impulso de inteligência artificial, as ações da desenvolvedora de software alemã SAP dispararam, elevando seu valor de ...
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...
German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback